EpiCast Report: Chronic Myeloid Leukemia - Epidemiology Forecast to 2022



Summary



Chronic Myeloid Leukemia (CML) is a rare cancer of the white blood cells characterized by increased and unregulated growth of myeloid cells originating in the bone marrow that invade the blood and potentially other organs, depending on the phase of the cancer (ACS, 2012; NLM, 2012). Based on clinical characteristics and laboratory findings, CML is divided into three phases: chronic, accelerated, and blast crisis; most people with CML are diagnosed at the chronic phase (NLM, 2012). The diagnosis of CML is based on the presence of the Philadelphia (Ph) chromosome, which is the product of a distinctive cytogenetic abnormality where the BCR gene on chromosome 22 becomes fused to the ABL gene on chromosome 9, generating the BCR-ABL fusion oncogene, which produces the BCR-ABL protein and triggers CML. The Ph chromosome is present in 95% of CML patients (Jabbour and Kantarjian, 2012; Sawyers, 1999).

GlobalData forecasts that the number of incident cases of CML in the 7MM will increase by 15.1% over the next decade, from 10,645 cases in 2012 to 12,252 cases in 2022. The number of five-year prevalent cases of CML in the 7MM will increase from approximately 45,000 cases to more than 51,000 cases throughout the forecast. In addition, the number of 10-year prevalent cases of CML in the 7MM will increase by 15.2% from 2012 to 2022. Country-specific registries are currently updating their CML prevalence data to reflect improved survival due to tyrosine kinase inhibitor therapy. As a result, the forecast number of prevalent cases of CML may increase toward the end of the forecast period as the disease survival continues to improve.



Scope


- The chronic myeloid leukemia (CML) EpiCast Report provides an overview of the risk factors and global trends associated with CML in the seven major markets (US, France, Germany, Italy, Spain, UK, and Japan).
- It also includes a 10-year epidemiological forecast of the incident and five- and 10-year prevalent cases of CML segmented by sex and age (by five-year increments for all age groups) in the seven major markets.



Reasons to buy


- Develop business strategies by understanding the trends shaping and driving the global CML market.
- Quantify patient populations in the global CML market to improve product development, pricing, and launch plans.
- Organize sales and marketing efforts by identifying sex and age groups that present the best opportunities for CML therapeutics in each of the markets covered.

Table Of Contents

Table of Contents

1 Table of Contents 4
1.1 List of Tables 6
1.2 List of Figures 6
2 Introduction 7
2.1 Catalyst 7
2.2 Upcoming Reports 8
3 Epidemiology 9
3.1 Disease Background 9
3.2 Risk Factors and Comorbidities 10
3.2.1 Exposure to ionizing radiation may not lead to the development of CML 10
3.2.2 Obesity and weight gain in adulthood play important roles in CML risk 11
3.3 Global Trends 12
3.3.1 Incidence 12
3.3.2 Prevalence and Survival 13
3.3.3 Mortality 14
3.4 Forecast Methodology 15
3.4.1 Sources Used 16
3.4.2 Forecast Assumptions and Methods, Incident Cases 17
3.4.3 Forecast Assumptions and Methods, Prevalent Cases 19
3.4.4 Sources Not Used 20
3.5 Epidemiological Forecast of Chronic Myeloid Leukemia (2012-2022) 20
3.5.1 Incident Cases of Chronic Myeloid Leukemia 20
3.5.2 Incident Cases of Chronic Myeloid Leukemia by Age Group 22
3.5.3 Incident Cases of Chronic Myeloid Leukemia by Sex 24
3.5.4 Age-Standardized Incidence Rates of Chronic Myeloid Leukemia 25
3.5.5 Incident Cases of Chronic Myeloid Leukemia with Ph+ 27
3.5.6 Incident Cases of Chronic Myeloid Leukemia by Phase at Diagnosis 28
3.5.7 Prevalent Cases of Chronic Myeloid Leukemia 29
3.6 Discussion 33
3.6.1 Epidemiological Forecast Insight 33
3.6.2 Limitations of the Analysis 34
3.6.3 Strengths of the Analysis 35
4 Appendix 36
4.1 Bibliography 36
4.2 About the Authors 39
4.2.1 Epidemiologists 39
4.2.2 Reviewers 40
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis 40
4.2.4 Global Head of Healthcare 41
4.3 About GlobalData 42
4.4 About EpiCast 42
4.5 Contact Us 42
4.6 Disclaimer 43



List of Tables

Table 1: Reported Incidence of Chronic Myeloid Leukemia for the US, 5EU, and Japan 12
Table 2: US, Annual Percentage Change (APC) in CML Mortality Rates, by Sex, Ages 0-85+ Years, %, 1993-2008 14
Table 3: 7MM, Sources of CML Incidence and Prevalence Data 15
Table 4: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+ Years, Men and Women, N, 2012-2022 21
Table 5: 7MM, Incident Cases of CML, by Age Group, Men and Women, N (Column %)*, 2012 22
Table 6: 7MM, Incident Cases of CML, by Sex, 0-85+ Years, N (Row %), 2012 24
Table 7: 7MM, Incident Cases of CML, by Ph+, Men and Women, 0-85+ Years, N, 2012 27
Table 8: 7MM, Incident Cases of CML, by Phase at Diagnosis, Men and Women, 0-85+ Years, N, 2012 28
Table 9: 7MM, Five- and 10-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ?0 Years, Men and Women, N, 2012-2022 31



List of Figures

Figure 1: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+ Years, Men and Women, N, 2012-2022 21
Figure 2: 7MM, Incident Cases of Chronic Myeloid Leukemia, by Age Group, Men and Women, N, 2012 23
Figure 3: 7MM, Incident Cases of Chronic Myeloid Leukemia, Ages 0-85+, By Sex , N, 2012 25
Figure 4: 7MM, Age-Standardized Incidence of Chronic Myeloid Leukemia, Ages ?0 Years, Men and Women , N , 2012 26
Figure 5: 7MM, Incident Cases of Chronic Myeloid Leukemia, by Phase at Diagnosis, Ages 85+ Years, Men and Women, N, 2012 29
Figure 6: 7MM, Five-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ?0 Years, Men and Women, N, 2012-2022 32
Figure 7: 7MM, 10-Year Prevalent Cases of Chronic Myeloid Leukemia, Ages ?0 Years, Men and Women, N, 2012-2022 32

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Clare

+1 339 368 6001

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.